CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 202 enrolled
Drug / intervention
Travoprost 0.004%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01493427
NCT01493427Phase 4Completed
CompareCT.gov

Multi-Center Study Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (0.004% Travoprost) in Patients Previously on Latanoprost 0.005% or Bimatoprost 0.01% Ophthalmic Solution Monotherapy

Alcon Research·interventional·Posted Dec 16, 2011·Updated May 19, 2014

In Brief

A Phase 4 clinical trial evaluating Travoprost 0.004% for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 202 participants.

Detailed Summary

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 16, 2011
Enrollment StartDec 1, 2011
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.5 years ago

Interventions

Travoprost 0.004%drug

Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative